Advertisement


Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Building on Recent Successes

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute, discusses the encouraging data on atezolizumab plus nab-paclitaxel in the first-line setting for metastatic triple-negative breast cancer, and the potential benefits of combining immune checkpoint inhibitors with targeted treatment in breast cancer.



Related Videos

Lung Cancer
Immunotherapy

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

Edward B. Garon, MD, of the Olive View–UCLA Medical Center, discusses phase IIIb/IV study findings on reducing the frequency of nivolumab dosing, from 480 mg every 4 weeks to 240 mg every 2 weeks, in patients with previously treated advanced non–small cell lung cancer (Abstract 100).

Immunotherapy

Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

Jedd D. Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the data to date on checkpoint blockades and the rationale for combination therapies and novel agents.

Immunotherapy

Kim A. Margolin, MD, on Promising Immunotherapy Strategies

Kim A. Margolin, MD, of City of Hope, summarizes a session she co-chaired on combination immunotherapies, locoregional therapies, systemic therapies, and enhancing natural killer cells.

CNS Cancers
Immunotherapy

Madhav V. Dhodapkar, MBBS, on Cancer Vaccines: Emerging Trends

Madhav V. Dhodapkar, MBBS, of Emory University, summarizes a session he co-chaired on emerging approaches for vaccines, personalized/neoantigen vaccines, and mutation-targeted immunotherapy for diffuse midline gliomas.

Bladder Cancer
Immunotherapy

Nicholas Vogelzang, MD, on Urothelial Cancer: Results From a Trial on Lenvatinib Plus Pembrolizumab

Nicholas Vogelzang, MD, of the Comprehensive Cancer Centers of Nevada, discusses phase Ib/II findings on pembrolizumab and lenvatinib given to 20 patients with metastatic transitional cell carcinoma of the bladder who had received no prior checkpoint inhibitor therapy (Abstract 11).

Advertisement

Advertisement



Advertisement